Small Cell Lung Cancer News and Research

RSS

Small cell lung cancer is a disease in which malignant (cancer) cells form in the tissues of the lung. Small cell lung cancer is an aggressive (fast-growing) cancer that can spread to other parts of the body. The cancer cells look small and oval-shaped when looked at under a microscope.

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

The drug ceritinib (trade name: Zykadia) has been approved since May 2015 for the treatment of adults with non-small cell lung cancer (NSCLC). It is an option when certain changes in the cancer cells (anaplastic lymphoma kinase-positive) stimulate tumour growth and patients have already been pretreated with crizotinib.

7 Oct 2015

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

Quest Diagnostics, the world’s leading provider of diagnostic information services, today announced that it will provide clinical laboratory testing using the PD-L1 IHC 22C3 PharmDx immunohistochemistry companion diagnostic.

From Quest Diagnostics 7 Oct 2015

OncoGenex meets target enrollment in apatorsen Phase 2 trial

OncoGenex Pharmaceuticals, Inc. announced today that Borealis-2, an investigator-sponsored, randomized Phase 2 trial, has met its target enrollment of 200 patients. Designed to evaluate apatorsen in combination with docetaxel in patients with advanced or metastatic bladder cancer who have disease progression following first-line platinum-based chemotherapy, Borealis-2 is sponsored by Hoosier Oncology Group and is being conducted at 27 sites across the United States.

30 Sep 2015

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, further data to support the efficacy of VARGATEF® (nintedanib*) in combination with docetaxel for the treatment of advanced non-small cell lung cancer (NSCLC) with adenocarcinoma histology

29 Sep 2015

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Boehringer Ingelheim today announced at the European Cancer Congress (ECC) in Vienna, Austria, new data from the Phase III LUX-Lung 8 trial which further highlights the benefits of afatinib compared to erlotinib for the treatment of patients with previously treated advanced SCC of the lung

29 Sep 2015

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

An international team of cancer researchers that included UT Southwestern Medical Center physicians announced "game-changing results" using the immunotherapy drug nivolumab to treat certain lung cancers that failed to respond to first-line therapies.

29 Sep 2015

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

Data presented today at the 2015 European Cancer Congress (ECC) demonstrates that the investigational immunotherapy atezolizumab may prevent progression of metastatic urothelial bladder cancer (mUBC) in all age groups by 2.1 months.

29 Sep 2015

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

Boehringer Ingelheim announced today results of a new European survey investigating therapy goals, prescribing habits and decision-making criteria of physicians treating patients with advanced lung cancer with adenocarcinoma histology after first-line chemotherapy.

29 Sep 2015

New targeted therapy shows promise against small cell lung cancer

Small cell lung cancer (SCLC) is an aggressive disease that is difficult to treat and is frequently only diagnosed when it has spread to other parts of the body (metastasised). Five-year survival rates in SCLC, which accounts for about 14% of all lung cancers, are very low, at only six percent. But today US researchers will present two novel findings with important implications for treatment at the 2015 European Cancer Congress.

29 Sep 2015

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Roche has announced the commercial availability in countries that accept the CE mark1 of the cobas® EGFR Mutation Test v2, the first oncology assay from Roche that utilises either plasma or tumour tissue as a sample. The test identifies 42 mutations in the epidermal growth factor receptor (EGFR) gene, the most of any In-vitro Diagnostic (IVD) on the market, and can also be used as an aid in selecting eligible patients with non-small cell lung cancer (NSCLC) for therapy with an EGFR tyrosine kinase inhibitor (TKI).

From Roche Sequencing and Life Science 28 Sep 2015

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Clinical trial results from Array BioPharma's wholly-owned MEK inhibitor, binimetinib, and BRAF inhibitor, encorafenib, were presented this weekend at the European Society of Medical Oncology's annual European Cancer Conference (ECC). At the meeting, preliminary data were shared from both a Phase 2 combination trial of binimetinib and encorafenib in BRAF-mutant melanoma patients (LOGIC2) and a Phase 1b/2 combination trial of binimetinib and ribociclib (Novartis, LEE011), a CDK4/6 inhibitor in NRAS-mutant melanoma patients.

28 Sep 2015

$Atezolizumab may change treatment strategies for refractory lung cancer patients$

Atezolizumab may change treatment strategies for refractory lung cancer patients

Atezolizumab is set to substantially change treatment strategies for patients with refractory lung cancer, according to Dr Martin Reck, Chief Oncology Physician in the Department of Thoracic Oncology, Hospital Grosshansdorf, Germany. Reck's comments came as the results from the POPLAR and BIRCH studies showing the first results of efficacy with atezolizumab across lines were presented at the European Cancer Congress 2015 (ECC 2015) in Vienna, Austria.

28 Sep 2015

Nivolumab drug improves survival for non-SQ NSCLC patients

Patients with a type of lung cancer called non-squamous non-small cell lung cancer (non-SQ NSCLC) have limited treatment options and a dismal prognosis once their disease has advanced and initial treatment with platinum-based chemotherapy has failed. Second-line treatment is usually with another chemotherapy drug, such as docetaxel or pemetrexed.

28 Sep 2015

Portuguese researchers find significant differences between smokers and non-smokers who develop NSCLC

Tobacco smoke is known to be the main risk factor for non-small cell lung cancer (NSCLC), although non-smokers can get it too. The incidence among non-smokers is increasing in many countries. Now a group of Portuguese researchers has found significant differences in clinical particularities and survival between smokers and non-smokers who develop NSCLC.

28 Sep 2015

Smokers who have COPD may face increased risk of getting small cell lung cancer

Smokers who have chronic obstructive pulmonary disorder (COPD) may face nearly twice the risk of getting small cell lung cancer (SCLC)--the deadliest form of lung cancer--than smokers who don't have COPD, according to a large worldwide study led by researchers at the Harvard T.H. Chan School of Public Health.

26 Sep 2015

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

For the first time, an immune checkpoint inhibitor has been proven to increase survival among patients with advanced renal cell carcinoma (RCC), a patient population for whom treatment options are currently limited.

26 Sep 2015

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

OncoGenex Pharmaceuticals, Inc. announced today initial results from the Phase 2 Rainier study evaluating apatorsen in combination with ABRAXANE (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) and gemcitabine compared to ABRAXANE and gemcitabine alone in patients with untreated metastatic pancreatic cancer.

23 Sep 2015

BGB324 shows enhanced tumour clearance in mouse carcinoma models

BerGenBio AS, an oncology biopharmaceutical company, has announced new preclinical data on lead compound, BGB324, in combination with immune checkpoint inhibitors, has been presented as a poster at CRI-CIMT-EATI-AACR - The Inaugural International Cancer Immunotherapy Conference: Translating Science into Survival, in New York.

21 Sep 2015

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

Cancer Treatment Centers of America at Western Regional Medical Center in Goodyear, Arizona, has begun Phase II of another arm of its multi-arm clinical trial that combines immunotherapy with chemotherapy.

21 Sep 2015

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

PharmaMar announced today the start of a multicenter, international, open-label, exploratory phase II "Basket" trial (NCT02454972) to evaluate the efficacy and safety of the anticancer agent PM1183 (lurbinectedin) in advanced solid tumors.

18 Sep 2015

Small Cell Lung Cancer News and Research

IQWiG finds no added benefit for ceritinib drug in adults with NSCLC

Quest Diagnostics provides PD-L1 IHC 22C3 PharmDx test service for NSCLC patients

OncoGenex meets target enrollment in apatorsen Phase 2 trial

Reducing tumor burden in lung cancer patients with advanced adenocarcinoma

GIOTRIF shows superior survival compared to Tarceva for patients previously treated with advanced squamous cell lung carcinoma

Clinical trial shows nivolumab drug improves overall survival, quality of life in lung cancer patients

Phase II IMvigor 210 data shows atezolizumab may prevent progression of metastatic urothelial bladder cancer

European survey sheds light on decision-making criteria of physicians treating advanced lung cancer patients

New targeted therapy shows promise against small cell lung cancer

Roche launches the cobas EGFR Mutation Test v2 for use with either plasma or tumour tissue samples

Clinical trial data from Array BioPharma's binimetinib and encorafenib presented at ECC 2015

Atezolizumab may change treatment strategies for refractory lung cancer patients

Nivolumab drug improves survival for non-SQ NSCLC patients

Portuguese researchers find significant differences between smokers and non-smokers who develop NSCLC

Smokers who have COPD may face increased risk of getting small cell lung cancer

Immune checkpoint inhibitor increases survival in patients with advanced renal cell carcinoma

OncoGenex reports results from Phase 2 Rainier study in patients with untreated metastatic pancreatic cancer

BGB324 shows enhanced tumour clearance in mouse carcinoma models

CTCA at Western begins clinical trial that combines immunotherapy with chemotherapy to target sarcomas

PharmaMar begins phase II 'Basket' trial to evaluate safety, efficacy of PM1183 in advanced solid tumors

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer

Latest News